Brief: NRx Pharmaceuticals Reports Recommendations Of Data Safety Monitoring Board For Trial Of NRX-101
02/02/2023 11:54
Feb 2 (Reuters) - NRX Pharmaceuticals Inc NRXP.O :
* NRX PHARMACEUTICALS REPORTS RECOMMENDATIONS OF DATA SAFETY
MONITORING BOARD FOR TRIAL OF NRX-101 IN PATIENTS WITH SEVERE
BIPOLAR DEPRESSION AND SUBACUTE SUICIDAL IDEATION OR BEHAVIOR
* NRX PHARMACEUTICALS INC-INDEPENDENT DATA SAFETY MONITORING
BOARD
IDENTIFIED NO SAFETY CONCERNS, ISSUED A RECOMMENDATION TO
CONTINUE TRIAL ENROLLMENT
* NRX PHARMACEUTICALS INC - NO TREATMENT-RELATED SERIOUS
ADVERSE
EVENTS WITH FIRST 50 ENROLLED CLINICAL TRIAL PARTICIPANTS
Source text for Eikon: ID:nPn38smY7a
Further company coverage: NRXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NRX Pharmaceuticals
See all newsBrief: NRx Pharmaceuticals Reschedules Conference Call To Discuss Third Quarter And Year To Date 2024 Financial Results To November 18, 2024
U.S. RESEARCH ROUNDUP-Cintas Corp, Sprouts Farmers market, Voya Financial
U.S. STOCKS ON THE MOVE-Molson Coors, Starbucks, Warner Bros Discovery
U.S. STOCKS ON THE MOVE-Zebra Technologies, Ecolab, American Electric Power
NRX Pharmaceuticals Inc expected to post a loss of 7 cents a share - Earnings Preview